RecruitingNCT04232566

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1


Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Feb 20, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.


Eligibility

Min Age: 30 YearsMax Age: 70 Years

Inclusion Criteria6

  • Undergoing gastric bypass surgery
  • Confirmed AUROC F=0 or F\>2 liver fibrosis
  • Age 30-70 years
  • BMI greater than 40 kg/m2
  • Negative pregnancy test (female only)
  • Lab Values: Normal TSH

Exclusion Criteria11

  • Autoimmune diseases
  • Hepatitis B or C positive
  • Heavy alcohol use
  • Active smoking history
  • Active cancer history
  • History of asthma
  • History of COPD
  • Taking Plavix or Coumadin
  • Blood donation within past 2 months
  • Glucocorticoid Therapy
  • Taking antihistamine on regular basis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBariatric surgery

Evaluate liver fibrosis by elastography before gastric bypass surgery.


Locations(1)

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04232566


Related Trials